MetaCap

ProQR Therapeutics N.V. (PRQR)

NASDAQ: PRQRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.04-0.01 (-0.95%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRQR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$146.98M
EPS (TTM)
-$0.43
52-week range
1.00 – 2.49
Day range
1.00 – 1.07
Volume / Avg
920.56K / 793.64K
Beta
—

52-week range

$1.00$2.49

PRQR stock today

ProQR Therapeutics N.V. (PRQR) closed at $1.04 on Nov 20, down 0.95% (-$0.01), versus the S&P 500's 3.70% decline. Shares are 58.1% below their 52-week high of $2.49, set on Dec 16, 2025 and 4.0% above the 52-week low of $1.00, near the bottom of the past year's range. PRQR is down 48.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.5%.

ProQR Therapeutics N.V. has posted a net loss over the last twelve months (EPS of -$0.43), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About ProQR Therapeutics N.V.

Company profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel Anton de Boer
Headquarters
Leiden
Employees
186
IPO year
2014
Website
proqr.com

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$7.56+626.92%

  • Strong buy 1
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.12 vs $-0.11
Surprise
-9.09%

PRQR news

All PRQR news

ProQR Therapeutics N.V. peers

Health Care sector
PRQR peer companies
CompanyPrice% ChgMarket capCompare
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs PRQR
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs PRQR
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs PRQR
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs PRQR
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs PRQR
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs PRQR
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs PRQR
ZNTLZentalis Pharmaceuticals Inc.1.360.00%$133.64Mvs PRQR

Indexes, lists and sector

ProQR Therapeutics N.V. stock FAQ

What is ProQR Therapeutics N.V.'s stock price today?

PRQR last traded at $1.04 as of Nov 20, 4:00 PM EST, down 0.95% on the day. Prices are delayed at least 15 minutes.

Who is ProQR Therapeutics N.V.'s CEO?

Mr. Daniel Anton de Boer is the chief executive officer of ProQR Therapeutics N.V., which has about 186 employees.

What is the PRQR 52-week high?

The 52-week high for PRQR is $2.49 and the 52-week low is $1.00. The stock is currently 58.1% below its high.

Compare PRQR